JEPQ vs XBI
JPMorgan Nasdaq Equity Premium Income ETF vs SPDR S&P Biotech ETF
- • JEPQ pays a higher dividend yield (9.95%).
Side-by-side metrics
| Metric | JEPQ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 9.95% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $40.66B | $10.73B |
YTD return | 8.22% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.78 | 1.10 |
P/E ratio | 31.95 | — |
Last price | $60.28 | $164.01 |
Inception | — | — |
Issuer | JPMorgan | State Street |
JEPQ top holdings
| NVDA | NVIDIA Corp | 6.62% |
| AAPL | Apple Inc | 5.77% |
| MU | Micron Technology Inc | 5.53% |
| GOOG | Alphabet Inc Class C | 5.00% |
| MSFT | Microsoft Corp | 3.86% |
| AMD | Advanced Micro Devices Inc | 3.83% |
| AMZN | Amazon.com Inc | 3.64% |
| LRCX | Lam Research Corp | 2.86% |
| TSLA | Tesla Inc | 2.37% |
| META | Meta Platforms Inc Class A | 2.36% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About JEPQ
JEPQ (JPMorgan Nasdaq Equity Premium Income ETF) is Nasdaq-tilted equity income with options overlay. Managed by JPMorgan, the fund carries $40.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 9.95%. Its largest holding is NVIDIA Corp (NVDA), which represents 6.6% of the portfolio. Real Estate is the fund's largest sector exposure at 0.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.